News

Imbrium will leverage TetraGenetics’ proprietary TetraExpress system to advance monoclonal antibodies that target specific ion channels that are scientifically important in the modulation of pain sensation. The goal

TQJ230 was discovered by Ionis and has been co-developed to date by Akcea and Ionis. Novartis is now responsible for worldwide development and commercialization of this asset. Millions

THEMIS was conducted in over 19,000 patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack (myocardial infarction, MI) or stroke. Preliminary safety

As per the terms of the merger agreement, Roche will buy each share of Spark Therapeutics at a price of $114.50. Founded in 2013, Spark Therapeutics is engaged

Danaher seeks to help its customers solve complex challenges and enhance quality of life across the world. GE Biopharma offers instruments, consumables, and software to facilitate research, discovery,

Through the transaction, Ipsen will acquire Clementia’s key late-stage clinical asset palovarotene, which is an investigational retinoic acid receptor gamma (RARγ) selective agonist. Palovarotene is being developed for

Urovant plans to use the proceeds to fund ongoing development of its lead compound vibegron, for business development opportunities, and for general corporate purposes. “This financing provides Urovant

The FDA granted priority review and set a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2019. The application is supported by comprehensive data from

As part of an exclusive, global strategic collaboration and option agreement, AbbVie and Voyager will develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein to treat Parkinson’s